46185-24-4

Basic information

• Product Name: 1,2,3,4-TETRAHYDRO-QUINOLINE-2-CARBOXYLIC ACID
• Synonyms: 1,2,3,4-TETRAHYDRO-QUINOLINE-2-CARBOXYLIC ACID;2-Quinolinecarboxylic acid, 1,2,3,4-tetrahydro-;1,2,3,4-tetrahydro-2-Quinolinecarboxylic acid
• CAS NO: 46185-24-4
• Molecular Formula: C₁₀H₁₁NO₂
• Molecular Weight: 177.2
• Mol File: 46185-24-4.mol
• Article Data: 15

Chemical Properties

• Melting Point: 112-113 °C
• Boiling Point: 392.598 °C at 760 mmHg
• Flash Point: 191.237 °C
• Appearance: /
• Density: 1.225
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.577
• Storage Temp.: 2-8°C
• PKA: 2.15±0.20(Predicted)
• CAS DataBase Reference: 1,2,3,4-TETRAHYDRO-QUINOLINE-2-CARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 1,2,3,4-TETRAHYDRO-QUINOLINE-2-CARBOXYLIC ACID(46185-24-4)
• EPA Substance Registry System: 1,2,3,4-TETRAHYDRO-QUINOLINE-2-CARBOXYLIC ACID(46185-24-4)

Safety Data

• Hazardous Substances Data: 46185-24-4(Hazardous Substances Data)

Usage

Uses

1,2,3,4-Tetrahydroquinoline-2-carboxylic Acid is a useful chemical reagent, used in the production of Indoline-2-carboxamide derivatives as brain-penetrant inhibitors of Trypanosoma brucei.

InChI:InChI=1/C10H11NO2/c12-10(13)9-6-5-7-3-1-2-4-8(7)11-9/h1-4,9,11H,5-6H2,(H,12,13)

Upstream product

• 91-63-4 2-methylquinoline 
• 5470-96-2 quinoline 2-carbaldehyde 
• 89047-45-0 quinoline-2-carboxylic acid hydrochloride 
• 93-10-7 quinoline-2-carboxylic acid 
• 1133419-06-3 1,2,3,4-tetrahydro-quinoline-2-carboxylic acid ethyl ester hydrochloride 

Downstream Products

• 511230-72-1 6-bromo-1,2,3,4-tetrahydroquinoline-2-carboxylic acid methyl ester 
• 123811-87-0 1-(tert-butoxycarbonyl)-1,2,3,4-tetrahydroquinoline-2-carboxylic acid 
• 898533-09-0 (R)-(+)-N-[4-[4-(m-tolyl)piperazin-1-yl]butyl]-1-(benzyloxycarbonyl)-1,2,3,4-tetrahydroquinoline-2-carboxamide 
• 75493-95-7 (R)-(+)-1-(benzyloxycarbonyl)-1,2,3,4-tetrahydroquinoline-2-carboxylic acid 
• 92976-98-2 1,2,3,4-tetrahydroquinolic acid 
• 898533-06-7 (R)-(+)-N-[4-[4-(m-tolyl)piperazin-1-yl]butyl]-1,2,3,4-tetrahydroquinoline-2-carboxamide 
• 898533-10-3 (R)-(+)-N-[4-(4-phenylpiperazin-1-yl)butyl]-1,2,3,4-tetrahydroquinoline-2-carboxamide 
• 552859-04-8 2-((4-(2-Bromo-5-isopropoxybenzyl)piperidin-1-yl)carbonyl)-1,2,3,4-tetrahydroquinoline 
• 123811-88-1 3,4-Dihydro-2H-quinoline-1,2-dicarboxylic acid 1-tert-butyl ester; compound with dicyclohexyl-amine 
• 157521-46-5 2-methyl (S)-(-)-1-(benzyloxycarbonyl)-1,2,3,4-tetrahydroquinoline-2-carboxylate 
• 92977-00-9 (2R)-1,2,3,4-tetrahydroquinoline-2-carboxylic acid 
• 185854-45-9 2-(1,2,3,4-tetrahydroquinolin-2-yl)acetic acid 
• 150533-87-2 6-bromo-5-<(methoxycarbonyl)methyl>-6,7-dihydro-1H,5H-pyrido<1,2,3-de>quinoxaline-2,3-dione 
• 63492-81-9 methyl (2R)-1,2,3,4-tetrahydroquinoline-2-carboxylate 

Relevant articles and documents

Design, synthesis and biological evaluation of novel thiohydantoin derivatives as potent androgen receptor antagonists for the treatment of prostate cancer

Prostate cancer (PC) is the most common malignancy in men worldwide. Here, two series of novel thiohydantoin derivatives of enzalutamide as potent androgen receptor (AR) antagonists were designed and synthesized. Among them, compound 31c was identified as an AR antagonist which is 2.3–fold more potent than enzalutamide. Molecular docking studies were performed to explain the improved potency of 31c at AR. In cell proliferation assays, 31c exhibited similar anti-proliferative activities with enzalutamide against hormone sensitive LNCaP cells and AR-overexpressing LNCaP/AR cells. These data indicate that 31c can be a good lead compound for further structure optimization for the treatment of prostate cancer.

THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE

Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.

THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE

Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.